Compare IDYA & BFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | BFH |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | 2019 | N/A |
| Metric | IDYA | BFH |
|---|---|---|
| Price | $34.67 | $72.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 17 |
| Target Price | $49.33 | ★ $70.20 |
| AVG Volume (30 Days) | ★ 964.1K | 885.5K |
| Earning Date | 02-12-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 1.25% |
| EPS Growth | N/A | ★ 55.00 |
| EPS | N/A | ★ 9.68 |
| Revenue | $214,834,000.00 | ★ $2,509,000,000.00 |
| Revenue This Year | $2,688.43 | $58.62 |
| Revenue Next Year | N/A | $3.51 |
| P/E Ratio | ★ N/A | $7.61 |
| Revenue Growth | ★ 5377.66 | 1.70 |
| 52 Week Low | $13.45 | $38.21 |
| 52 Week High | $39.28 | $82.03 |
| Indicator | IDYA | BFH |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 46.43 |
| Support Level | $34.75 | $67.78 |
| Resistance Level | $37.81 | $74.17 |
| Average True Range (ATR) | 1.70 | 2.16 |
| MACD | -0.16 | -1.01 |
| Stochastic Oscillator | 31.09 | 30.88 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.